Inter-individual variability in drug response, be it efficacy or safety, is common and likely to
become an increasing problem globally given the growing elderly population requiring …

The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over
the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy …

Fibroblast growth factor receptors (FGFRs) are aberrantly activated through single-
nucleotide variants, gene fusions and copy number amplifications in 5–10% of all human …

Calix [n] arenes (n= 4, 5, 6, 8) are “chalicelike” phenol-based macrocycles that are among
the most fascinating and highly studied scaffolds in supramolecular chemistry. This stems …

Cancer is driven by genetic change, and the advent of massively parallel sequencing has
enabled systematic documentation of this variation at the whole-genome scale,–. Here we …

Background Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …

The past decade of cancer research has been marked by a growing appreciation of the role
of immunity in cancer. Mutations in the tumour genome can cause tumours to express …

Disease overview Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …

Purpose A dramatic improvement in the survival of patients with chronic myeloid leukemia
(CML) occurred after the introduction of imatinib mesylate, the first tyrosine kinase inhibitor …

Receptor tyrosine kinases (RTKs) play an important role in a variety of cellular processes
including growth, motility, differentiation, and metabolism. As such, dysregulation of RTK …